Few studies have evaluated the impact of new comorbidities, fragility and disability indices on transcatheter aortic valve replacement (TAVI) outcomes. This study analyzes Medtronic CoreValve U.S. Pivotal patients to develop a new, simpler scoring system to use in addition to the standard assessment of TAVI patients. A multidisciplinary heart team used objective criteria, the<a href="https://solaci.org/en/2016/07/28/a-new-score-to-predict-post-tavi-mortality/" title="Read more" >...</a>
SAPIEN 3 for TAVR: Lower One-Year Mortality
Original Title: One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high risk and inoperable patients with severe aortic stenosis. Reference: Herrmann H et al. Circulation. 2016; Epub ahead of print. Data presented at this last TCT annual meeting about the low rate of events at one year in inoperable patients with<a href="https://solaci.org/en/2016/07/25/sapien-3-for-tavr-lower-one-year-mortality/" title="Read more" >...</a>
Post TAVR AVB: Is Telemetry Monitoring Necessary?
Original Title: The Electrocardiogram after Transcatheter Aortic Valve Replacement Determines the Risk for Post-Procedural High-Degree AV Block and the Need for Telemetry Monitoring Reference: J Am Coll Cardiol Intv. 2016;9(12):1269-1276. Courtesy of Dr. Agustín Vecchia. So far, we have not been able to determine the moment high degree atrioventricular block (AVB) takes place after<a href="https://solaci.org/en/2016/07/22/post-tavr-avb-is-telemetry-monitoring-necessary/" title="Read more" >...</a>
Low gradient and LV Dysfunction: TAVI or not?
Original Title: Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement. Reference: Baron SJ et al. J Am Coll Cardiol. 2016;67:2349-2358. Low aortic valve gradient and left ventricular dysfunction are frequent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVI) but only low aortic valve<a href="https://solaci.org/en/2016/06/02/low-gradient-and-lv-dysfunction-tavi-or-not/" title="Read more" >...</a>
TAVI in Low-Flow / Low-Gradient
Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a<a href="https://solaci.org/en/2016/04/14/tavi-in-low-flow-low-gradient/" title="Read more" >...</a>
TAVI: Good Outcomes with Intermediate Risk
Original Title: Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement in Intermediate-Risk Patients: A Propensity Score Analysis. Reference: Vinod H Thourani et al. Lancet Published Online April 3, 2016. Courtesy of Dr. Carlos Fava. The transcatheter Aortic Valve Replacement (TAVI) has shown benefits in high risk patients or inoperable patients, but there is little evidence<a href="https://solaci.org/en/2016/04/13/tavi-good-outcomes-with-intermediate-risk/" title="Read more" >...</a>
TAVI in ≥90 year old patients: as beneficial as in younger patients
Original Title: Should Transcatheter Aortic valve replacement Be Performed in Nonagenarians? Insights from the STS/ACC TVT Registry. Reference: Mani Arsalan et al. J Am Coll Cardiol. 2016 Mar 29;67(12):1387-95. Courtesy of Dr. Carlos Fava The benefit of the transcatheter aortic valve replacement (TAVI) has already been shown in the general population undergoing this procedure. The number<a href="https://solaci.org/en/2016/04/12/tavi-in-%e2%89%a590-year-old-patients-as-beneficial-as-in-younger-patients/" title="Read more" >...</a>
New York TAVR Registry: Trends in use and mortality at one year
Original Title: Utilization and 1-Year Mortality for Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement in New York Patients With Aortic Stenosis2011 to 2012. Reference:Hannan EL et al. J Am CollCardiolIntv. 2016;9(6):578-585. Courtesy of Dr. Agustín Vecchia It’s been only 14 years sinceCribierperformed the first transcatheter valve replacement. Today, during 2016, 100,000 patients are expected to<a href="https://solaci.org/en/2016/04/08/new-york-tavr-registry-trends-in-use-and-mortality-at-one-year/" title="Read more" >...</a>
PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients
Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with severe symptomatic aortic stenosis. For those that can be accessedfemorally, TAVI seems even better than surgery. In all, 2032 intermediate risk patients were randomized in 57 centers to TAVI with Sapien<a href="https://solaci.org/en/2016/04/08/partner-2a-tavi-not-inferior-to-surgery-in-intermediate-risk-patients/" title="Read more" >...</a>
PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox
A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, compared to younger patients. In fact, patients over 90 undergoing TAVI have the same life expectation of someone the same age with no aortic stenosis. In-hospital<a href="https://solaci.org/en/2016/04/08/partner-1-in-90-year-old-patients-tavi-and-the-age-paradox/" title="Read more" >...</a>